Biotech Investing for Wholesale Investors

Biotech sits at the meeting point of capital and one of the most durable tailwinds in markets: an ageing global population and the scientific breakthroughs, in genomics, immunology and platform therapeutics, aimed at treating disease. The upside on a successful program can be large, but biotech is also one of the highest-risk corners of investing, where clinical and regulatory outcomes are often binary.

Boston Global Wealth clients access biotech selectively, through specialist managers and diversified vehicles rather than single-company bets, with allocations sourced through the Boston Global Group network, which includes the FSHD Global Research Foundation founded by BGW Chairman Bill Moss AO. It is risk capital, sized modestly within a broader portfolio, and losses on individual names are possible. This page is general advice only.

What it is

Equity and venture exposure to companies developing therapeutics, diagnostics, genomics and platform technologies in human health. The opportunity set spans listed biotech, late-stage private companies approaching trial readouts or launch, and earlier-stage ventures backing breakthrough science.

Why investors consider it

Therapeutic markets are large, durable and growing. A successful clinical milestone, acquisition or IPO can return a multiple of the capital in a single position. The trade-off is high variance: many programs fail, so outcomes are uneven and returns are not guaranteed.

How the exposure is built

Through specialist healthcare venture and growth funds on the approved list, diversified late-stage private-shares strategies that include biotech alongside other themes, and selective direct allocations sourced through the Boston Global Group network in the medical-research community.

How BGW manages the risk

Biotech is treated as risk capital: sized modestly against the whole portfolio, held in diversified vehicles wherever possible, and allocated to managers with genuine scientific depth and the patience to underwrite long development cycles.

Where it fits

A small, high-risk growth sleeve for investors who can accept that individual positions may fail entirely, in exchange for exposure to the occasional outsized success.

Risks to weigh

Biotech is high-risk by nature. The main risks to weigh:

Clinical-trial risk. Outcomes are often binary; a failed trial can sharply reduce or wipe out a company's value.
Regulatory risk. Approvals from the TGA, FDA or equivalents can be delayed or refused.
Long timelines and illiquidity. Development can take many years, and private positions are illiquid until an exit.
Concentration risk. Single-company outcomes can dominate returns; a total loss on a name is possible.
Financing and dilution risk. Biotechs consume cash and often raise more capital, diluting existing holders.
Commercial risk. Even approved products can disappoint on pricing, reimbursement or uptake.

Frequently asked questions

What is biotech investing?

Biotech investing means backing companies developing new therapies, diagnostics and health platforms, through listed shares, private funds or venture capital. Investors aim to benefit from successful clinical and commercial milestones.

Why is biotech considered high risk?

Because outcomes are often binary and depend on clinical trials and regulatory approvals. A single result can move a company's value dramatically, and many programs never reach market.

How do Australian wholesale investors access biotech?

Typically through specialist healthcare venture and growth funds, or diversified late-stage private strategies that include biotech, rather than concentrated single-company positions.

Can I lose all my money in biotech?

Yes, an individual biotech company can fail and that position can go to zero. That is why BGW favours diversified vehicles and sizes biotech as modest risk capital within a broader portfolio.

Who can invest in these biotech strategies?

They are generally restricted to wholesale or sophisticated investors as defined under section 708 of the Corporations Act.

General advice only. This information does not consider your objectives, financial situation or needs; consider the relevant disclosure document and seek personal advice before investing. Any target returns are indicative only and not guaranteed. Past performance is not a reliable indicator of future performance. Private market investments carry liquidity, valuation and concentration risks and are generally restricted to wholesale or sophisticated investors under section 708 of the Corporations Act.